Oculis Holding AG
Oculis Holding AG (OCS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · OCS · as of Jun 8, 2026
Key Statistics
Explore Oculis Holding AG Data
ocs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 100.0%
The OCS analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $39.40, representing +267.88% upside from the current price of $10.71.
Competitors & Peers
ocs competitorsOCS
ANAB
BBOT
KOD
MNMD
NKTRStock Performance
Full HistoryAbout Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the a…
what is oculis holding ag · ocs stock overview · oculis holding ag company profile · who is oculis holding ag ceo · ocs NASDAQ · oculis holding ag headquarters · oculis holding ag business segments
About Stock Overview & Key Data
Oculis Holding AG (OCS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 18, 2021. As of the latest trading session, OCS stock price is $10.71, with a market capitalization of $612.3M. The stock has returned -46.80% over the past 12 months and -46.94% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Oculis Holding AG stock is Buy, with an average 12-month price target of $39.40. In fiscal year 2025, Oculis Holding AG reported revenue of — and net income of -$94.5M. For detailed data — including Oculis Holding AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Oculis Holding AG (OCS) stock price is $10.71. The stock is traded on NASDAQ under the ticker symbol OCS. The 52-week range is $10.52 – $34.48.